Adaptimmune Therapeutics plc ADAPY
0.02 USD 0.00 (-5.00%)
At closeNov 5, 2026, 4:00 PM EST
0.0171 Day range 0.0189
0.001 52-week range 0.07
- YTD
- -26.92%
- 1 year
- -47.22%
News
newsfilecorp.com Adaptimmune Announces Changes to Board and Executive Leadership Team Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes…
businesswire.com AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.
newsfilecorp.com Adaptimmune Announces Delisting from Nasdaq Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the…
newsfilecorp.com Adaptimmune Reports Q2 Financial Results and Provides Business Update Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to…
newsfilecorp.com Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase…
seekingalpha.com Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer…
newsfilecorp.com Adaptimmune Reports Q1 Financial Results and Provides Business Update TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of…
newsfilecorp.com Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with…
seekingalpha.com Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial…
newsfilecorp.com Adaptimmune Provides Q4 and Full Year 2024 Business Update TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA…
newsfilecorp.com Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with…
newsfilecorp.com Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor…
newsfilecorp.com Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be…
newsfilecorp.com Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down…
newsfilecorp.com First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. -…
seekingalpha.com Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis…
newsfilecorp.com Adaptimmune Reports Q3 2024 Financial and Business Updates Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the…
newsfilecorp.com Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial 42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be…
newsfilecorp.com Adaptimmune to Participate in Scientific and Medical Conferences this November and December Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor…